It’s a big day for Sarepta Therapeutics (NASDAQ:SRPT) investors. The company released positive preliminary results from a gene therapy for Duchenne muscular dystrophy (DMD) …
Wave Life Sciences (NASDAQ:WVE) shares tumble nearly 14% in Tuesday’s trading session, following the news that competitor Sarepta (NASDAQ:SRPT) achieved impressive results in a Phase 1/2a gene therapy …
Can you feel the ground moving beneath your feet? Shares of Sarepta (NASDAQ:SRPT) skyrocketed nearly 60% this morning, following the announcement of positive …
Is SRPT a bull’s dream? Oppenheimer’s Hartaj Singh believes with commercial and clinical momentum into the new year, and no real DMD rivals for 3 to 5 years, the drug maker is a good bet.
Cantor: CELG pipeline needs commercial juice; Cowen: Sarepta soars on strong Exondys 51 orphan launch.
Sarepta shares dropped 4% after patient deaths revealed in the FDA FAERS database.
Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.
This hedge fund guru has made the right call on these three booming stocks.
Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech …
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring nearly 18% in pre-market trading Thursday, after the drug maker reported solid second-quarter earnings and provided a …
